Prevalence and spectrum of germline BRCA1 and BRCA2 mutations in multiethnic cohort of breast cancer patients in Brunei Darussalam
==================================================================================================================================
* Siti Nur Idayu Matusin
* Nuramalina Mumin
* Hazirah Zainal Abidin
* Fatin Nurizzati Mohd Jaya
* Lu Zen Huat
* Mas Rina Wati Haji Abdul Hamid
## Abstract
This is the first genetic study of its kind in Brunei Darussalam. *BRCA1* and *BRCA2* genes are the most well-known and well described predictors of hereditary breast cancer due to their clinical importance. This study aimed to identify the prevalence and mutation spectrum of the *BRCA1* and *BRCA2* germline mutations among 120 unselected series of Brunei breast cancer patients. We screened the entire coding region of *BRCA1* and *BRCA2* gene using Sanger sequencing and next-generation sequencing methods, and identified three pathogenic and one likely pathogenic mutations in the *BRCA2* gene. Of the 120 patients, 6 (5%) were *BRCA2* carriers which confirm that *BRCA2* carriers are more common in the Asian population compared to the Caucasian population. One *BRCA2* mutation observed only in the Chinese ethnicity of the Brunei breast cancer population contributes to the probability of the mutation being a founder effect in the Southern Chinese population. Brunei *BRCA2* carriers were more likely to have a positive family history of breast and/or ovarian cancers and have more than one family members in the first-degree relatives diagnosed with breast cancer.
## Introduction
Breast cancer is the most common cancer affecting women worldwide with varying incidence rates across the world [1]. Among the breast cancer risk factors, genetic predisposition confers the highest risk in breast cancer progression [2]. About 5-10% of breast cancers are inherited with approximately 30% of the inherited breast cancers were attributed to germline mutations in high penetrance breast cancer susceptibility genes, Breast Cancer susceptibility genes type 1 (*BRCA1*) [3]and Breast Cancer susceptibility genes type 2 (*BRCA2*) [4]. *BRCA1* and *BRCA2* are tumour suppressor genes (TSGs) that function by suppressing the growth of tumour cells via multiple DNA damage and repair pathways in the cells [5–10]. Notably, the BRCA1 protein is multi-functional as it also regulates cell cycle through a number of mechanisms [5,6,8,10–15].
*BRCA1* and *BRCA2* germline mutation carriers had an increased cumulative risk of 72% and 69%, respectively to develop breast cancer by 80 years old [16]. *BRCA1* and *BRCA2* carriers would also have an increased risk of developing ovarian, prostate, and pancreatic cancers [16]. Breast cancer patients who inherit germline mutations in these genes, in particular *BRCA1* carriers, are commonly associated with triple negative breast cancer (TNBC), diagnosed at an early age of onset (≤40 years), diagnosed with bilateral breast cancer, having family history of breast and/or ovarian cancers in the first- and second-degree relatives, and having an ovarian cancer [17–21]. The discovery of these two genes being linked to breast and ovarian cancers has led to the increased importance of genetic testing where continuous research and development had ultimately resulted in *BRCA1* and *BRCA2* genetic tests available at a more affordable cost and with a higher sensitivity and specificity [22]. Moreover, increased awareness on available personalised treatment for affected patients such as olaparib, an oral poly ADP ribose polymerase (PARP) inhibitor, which has been shown to provide a significant benefit over standard therapy among the *BRCA* mutation*-*carrier patients [23–24], has led to the increasing demand for rapid *BRCA* testing preferably at the first diagnosis [22]. This rapid increase caused pressure for diagnostic laboratories to provide a genetic test with a shorter turnaround time [22]. The two most commonly used platform for DNA sequencing are Sanger sequencing and Next-generation sequencing (NGS). Although NGS has largely overtaken Sanger sequencing due to its cost-effective ability in screening a larger set of samples in parallel and simultaneous screening of multiple cancer susceptibility genes in one sample, Sanger sequencing is still used in laboratories today when the main objective is to screen a single gene only.
Brunei Darussalam is a small country (5,765 sq km) on the Borneo Island, located in the South-east Asia (SEA) region, bordering the South China Sea and East Malaysia [25]. The population is estimated over 400,000, comprises 66% Malay, 10% Chinese, 3% other indigenous and 21% other ethnic groups [25]. Breast cancer was one of the top three leading causes of cancer mortality among women in Brunei Darussalam with an incidence rate (age-standardized rate [ASR]) of 55.9 per 100,000 women which is the second highest among countries in the SEA region, but considerably lower compared to the Western Europe (ASR, 90.7) [1,26]. Notably, the incidence rate of breast cancer in Brunei varies by ethnicity, with the highest rate observed in Chinese (ASR, 60.4) [27], followed by Malays (ASR, 48.1) [27], and Others (ASR, 12.3) [28]. There has not been any formal study conducted on finding the contribution of genetic and non-genetic factors in the rising incidence of breast cancer in Brunei. Therefore, studying various aspects of breast cancer in the Brunei patients could help to understand and determine the probable cause that leads to the rise in the incidence of the disease in the population, and in planning a better health care for the Brunei population. The contribution of genetics in breast cancer specifically in the involvement of susceptibility genes has been continuously researched on in the Western and developed Asian countries resulting in many reports on the spectrum of variants within the susceptibility genes from all over the world. In the SEA region, the mutation spectrum of *BRCA1* and *BRCA2* genes in breast cancer has been studied in Singaporean [18,19,29–31], Malaysian [21,32–37], Filipino [38,39], Vietnamese [40,41], Thai [42,43], and Indonesian [44,45] populations leading to the discovery of novel pathogenic variants from different ethnicities, suggesting the mutation spectrum of the *BRCA1* and *BRCA2* genes are still understudied. Furthermore, a number of the variants identified in the SEA breast cancer populations has also been found in other populations such as the African, European and American suggesting that they are not specific to the reported population, implying the genetic heterogeneity and randomness of the mutations. Interestingly, most of the variants identified in the breast cancer population in East Malaysia which is also located on the Borneo Island [33] were not identified in the West Malaysia population suggesting a difference in population genetics between East and West Malaysia.
Some of the variants identified in the Filipino breast cancer population who mostly were a combination of Malay and other population ancestry have also been proposed to be founder mutations due to the shared haplotype markers [39]. Currently, there are no genetic mutation data that report on the frequency of any genes related to breast cancer in Bruneian patients with or without family history. Thus, genetic contribution in breast cancer and other related cancers in Bruneian population remains uninvestigated. In this study, we investigated a population-based unselected series of Brunei breast cancer patients to determine the prevalence and spectrum of *BRCA1* and *BRCA2* mutations using Sanger and next-generation sequencing methods, and assess their association with sociodemographic, clinicopathological, and family history characteristics of the population.
## Materials and methods
### Study population
The study population includes unselected incident and prevalent breast cancer patients seen from 18th May 2012 until 30th January 2013, and from 23rd May 2016 until 19th November 2018 at The Brunei Cancer Centre (TBCC), Pantai Jerudong Specialist Centre (PJSC), the only cancer referral hospital in Negara Brunei Darussalam. Terminally-ill patients were excluded from the study. Among approximately 567 patients attending clinics during this period of time, a total of 164 patients were approached and explained about the study. Patient information sheet was provided and 121 patients consented as the final study participants. All study participants signed informed consent document. Peripheral blood samples and demographic and family history data were collected from the consenting patients. One patient was later excluded due to insufficient DNA sample to complete the *BRCA1* and *BRCA2* mutation analysis. Finally, 120 patients were included for the final analysis. Retrospective review of the study participants’ medical and histopathology records was conducted at TBCC with authorized permission from relevant authorities from 1st November 2018 to 9th January 2019. The records were available in the form of hard printed copy. The study was approved by the Brunei Darussalam Ministry of Health’s Medical and Health Research &Ethics Committee (MHREC).
### *BRCA1* and *BRCA2* mutational screening
S1 Fig shows a flow chart of the strategy used to detect mutations in the *BRCA1* and *BRCA2* genes in the study population. The samples from the first 66 study participants (henceforth referred to as Batch 1) were analysed by Sanger sequencing while the samples from the last 54 study participants (henceforth referred to as Batch 2) were sequenced by next-generation sequencing (NGS).
#### Sanger sequencing
Samples sequenced using Sanger sequencing utilised two workflows, PCR amplified with designed primers, and PCR amplified using EasySeqTM PCR Plates for *BRCA1/2* Sequencing (Nimagen, The Netherlands).
In the first workflow, the gDNA extracted using Wizard Genomic DNA purification kit (Promega) was amplified using AmpliTaq® 360 DNA Polymerase kit (Applied Biosystems) prior to sequencing. The details of the primers and PCR conditions used in this study have been described elsewhere[46–48]. The PCR products were resolved onto 1% agarose gel for evaluation of successful amplifications without contamination. The remaining PCR products were then purified using QIAGEN QIAquick® PCR Purification Kit.
In the second workflow, the gDNA extracted was amplified using the EasySeqTM PCR Plates for *BRCA1/2* Sequencing (Nimagen, The Netherlands) following the manufacturer’s protocol. The plate was used for sequencing to screen for mutations in the complete coding region including ±50bp up- and downstream of each *BRCA1* and *BRCA2* genes’ coding exon. All of the primers in the columns were tailed with universal tails – forward primers with −21M13 (5’-TGTAAAACGACGGCCAGT-3’) and reverse primers with M13Rev (5’-CAGGAAACAGCTATGACC-3’). PCR products from columns 1-10 were purified via ethanol/sodium acetate precipitation, and the pellets were resuspended with sterile water.
The purified PCR products from both workflows were used as the template for the Sanger sequencing reactions following the BigDye Terminator® v3.1 Cycle Sequencing Kit protocol (Applied Biosystems, USA). The sequencing products were purified using the Axygen AxyPrepTM Mag Dye Clean Up Kit. *BRCA1* and *BRCA2* Sanger sequencing was performed using the ABI 3500 Genetic Analyzer (Applied Biosystems, USA). The sequence data collected were processed and analysed using the 3500 Sequencing Analysis Software v5.2. Purified PCR products from the first workflow were sent for Sanger sequencing (First BASE Laboratories, Malaysia).
#### Next-generation sequencing (NGS)
The DNA samples sequenced by NGS were outsourced to Cancer Research Malaysia (CRM) for *BRCA1, BRCA2, TP53,* and *PALB2* targeted panel sequencing. The HBOC_4_v2 gene panel used was developed by CRM and the University of Melbourne and was used to screen for coding exons ±2 bp intronic sequence of the *BRCA1* (NM_007294.3)*, BRCA2* (NM_000059.3)*, PALB2* (NM_024675.3), and *TP53* (NM_000546.4) genes. Bioinformatic analysis was performed by CRM and the variant results excluding neutral polymorphisms were delivered upon completion.
#### Bioinformatic analysis
Sanger sequencing data obtained using Sequencing Analysis Software v5.2 and from First BASE Laboratories were aligned to the reference sequences of the gene obtained from the NCBI GenBank (*BRCA1* NCBI RefSeq = NG_005905.2 and *BRCA2* NCBI RefSeq = NG_012772.1) and nucleotide database (*BRCA1*NCBI RefSeq = NM_007294.3 and *BRCA2* NCBI RefSeq = NM_000059.3) using Variant Reporter Software v1.0 (Applied Biosystems, USA). All variants identified were annotated using the same software.
For samples sequenced by NGS, although CRM have analysed and validated the results, the data were re-analysed as neutral polymorphisms were not included in the provided results. The attainment of these results ensures the generation of a complete genetic variation profile for the patients.
Integrative Genomics Viewer (IGV) v2.5.2 (Broad Institute) was used to view the binary files provided by CRM. The data were analysed using the public server at usegalaxy.eu [49]. Variants were called using varscan (Galaxy Version 2.4.2) and bcftools call (Galaxy Version 1.9+galaxy 1). The data generated by bcftools call were filtered using VCFfilter. All variants identified from NGS were annotated using the SNPeff Eff tool (Galaxy Version 4.3+T.galaxy1).
All variants identified from Sanger sequencing and NGS were annotated according to the nomenclature used by the Human Genome Variation Society (HGVS) recommendation guidelines, using the A of the ATG translation initiation codon as nucleotide +1. All identified missense variants were analysed *in silico* using SIFT, PolyPhen-2, CADD, FATHMM-MKL, and DANN to predict the effect of amino acid substitution. Each prediction tool scored the missense variant as damaging or benign/neutral. All variants identified in this study were also checked against the NCBI ClinVar, Varsome, and population frequency databases (gnomAD and 1000 genome).
All variants identified in this study, underwent thorough assessment and review of available evidence (e.g. database information, and *in silico* predictions) following the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG) standards and guidelines for the interpretation of sequence variants [50] to arrive at a final variant classification of either pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, and benign. In this study, a variant was considered a pathogenic damaging mutation if it was a protein-truncating mutation caused by deleterious or frameshift mutation, or a missense mutation which has a confirmed association with the disease, or a missense variant which has been classified as likely pathogenic according to the ACMG standards and guidelines. All pathogenic mutations identified using Sanger sequencing were confirmed by repeating the Sanger sequencing using an independent sample, while pathogenic mutations identified using NGS were re-sequenced using Sanger sequencing. We selectively Sanger sequenced only the pathogenic mutations identified using NGS via our own ABI 3500 Genetic Analyzer. Notably, CRM had confirmed all variants other than neutral polymorphisms by Sanger sequencing.
#### Multiplex ligation-dependent probe amplification (MLPA)
Samples from Batch 1 were screened for large genomic rearrangements by MPLA using the SALSA MLPA P002 BRCA1 and SALSA MLPA P090 BRCA2 probe mix following the manufacturers’ protocol (MRC-Holland, Netherland). The MLPA analyses were performed by DNA Fragment Analysis on the ABI 3500 Genetic Analyzer. Data obtained were comparatively analysed using Coffalyser Net software v.140721.1958 (MRC-Holland, Netherland).
### Statistical analyses
Continuous data were presented as mean ± standard deviation (SD) or median and range where applicable. Mann-Whitney test was used to compare differences between the medians in two or more independent groups respectively. Chi-square or Fisher exact test was used to analyse the association between two independent variables in the population. The statistical analysis was performed using SPSS version 17.0 software for Windows. A p value <0.05 was considered statistically significant.
## Results
This was the first study of its kind in the Brunei breast cancer patients. Of the 120 recruited breast cancer patients, 94 (78.3%) were Malays, 19 (15.8%) were Chinese, and 7 (5.8%) were others. The mean age at diagnosis was 49.1±10.51 years, with peak of breast cancer incidence occurred in the 51-60 years old age group, and one (0.8%) was a male breast cancer (Table 1).
View this table:
[Table 1.](http://medrxiv.org/content/early/2024/10/13/2024.10.12.24315375/T1)
Table 1. Demographic characteristics, personal and family history of cancer of study population (*n*=120).
Seven (5.8%), two (1.7%), one (0.8%), and one (0.8%) patients had personal history of bilateral breast cancers, ovarian cancer, endometrium cancer, and liver cancer, respectively. Assessment of family history of breast and/or ovarian cancers was made based on whether the affected family members of the patients were their first and/or second-degree relatives. Of the 120 cases, 36 (30.0%) had family history of breast and/or ovarian cancers in their first and/or second-degree relatives while 47 (39.2%) had no family history of cancers at all. Of patients with family history of breast cancer, 17 (14.2%) had one first-degree family member affected with breast cancer, and 3 (2.5%) had two first-degree relatives affected with breast cancer. For patients with family history of ovarian cancer, 5 (4.2%) and 2 (1.7%) had only one affected member in the first- and second-degree relatives respectively (Table 1).
### *BRCA1* and *BRCA2* mutations
Of the 95 variants identified in the study population, 29 (30.5%) and 66 (69.5%) were *BRCA1* and *BRCA2* variants respectively (S1 – S4 Tables). Of the 29*BRCA1* and 66*BRCA2* variants, 11 (37.9%) and 22 (33.3%) were novel respectively (S2– S4 Tables). No large rearrangements were detected in this study.
#### Prevalence of pathogenic mutations and VUS
Our study identified three frameshift *BRCA2* deleterious mutations in 5 patients which led to the introduction of premature stop codon in the resulting BRCA2 protein (S1 Table, Fig 1 and S2 Fig), and one likely pathogenic *BRCA2* missense mutation in one patient (S2 Table and Fig 1). Therefore, the overall prevalence of germline *BRCA1* and *BRCA2* carriers among Brunei breast cancer patients were 0% and 5%, respectively. All of the identified pathogenic and likely pathogenic mutations have been reported, and were rare in the general population (<0.05% in gnomAD and 1000 Genome). One of the *BRCA2* deleterious mutations (c.5164_5165delAG) appeared to be a recurrent mutation.
[Fig 1.](http://medrxiv.org/content/early/2024/10/13/2024.10.12.24315375/F1)
Fig 1. Schematic presentation of identified *BRCA2* pathogenic mutations among Brunei breast cancer cases.
Excluding one patient with simultaneous germline pathogenic mutations, our study also identified 9*BRCA1* and 32 *BRCA2* VUS in 10and 31 patients, respectively (S3 Table). Thus, the prevalence of *BRCA1* and *BRCA2* VUS carriers among Brunei breast cancer patients were 8.3% and 25.8%, respectively. Four of the *BRCA1* VUS and 14 of the *BRCA2* VUS were novel while the others have been reported. Almost all of the reported VUS have no recorded data in the general population (S3 Table) while those that with data were found to be rare in the general population (<0.05% in gnomAD and 1000 Genome).
#### Characteristics of Brunei’s germline pathogenic *BRCA* carriers
S5 Table shows the characteristics of the Brunei breast cancer patients with deleterious and damaging missense mutations. Collectively, one (16.7%) of the carriers was male while the rest were female. Two (33.3%) of the affected were diagnosed with bilateral breast cancer. The molecular subtype of the first breast cancer diagnosis showed that one (16.7%) patient was TNBC, one (16.7%) was Luminal A, while the rest were Luminal B. Two (33.3%) of the carriers had an age at onset of ≤40 years while the others were ≥40 years, and one (16.7%) of the carriers had no family history of cancers at all. The proportion of our *BRCA1/2* carriers by ethnicity was 3/19 (15.8%) and 3/94 (3.2%) in Chinese and Malay, respectively.
There is no significant difference observed between the overall median age of diagnosis among carriers (48 years) and non-carriers (49 years) (*p*=0.609, Table 2). Brunei *BRCA2* carriers were found to be more likely to have family history of breast and/or ovarian cancer, and have≥1 affected family members in the first-degree with breast cancer (*p* = 0.027 and *p* = 0.001 respectively, Table 2). There are no significant association between Brunei *BRCA2* carriers and other selected clinical characteristics in Table 2.
View this table:
[Table 2.](http://medrxiv.org/content/early/2024/10/13/2024.10.12.24315375/T2)
Table 2. Association analysis of Brunei breast cancer patients with pathogenic mutation with selected clinical characteristics.
## Discussion
Prior to introducing cancer genetic test in a community, genetic variation profile of the said community must first be known to have an overview of the contribution of genetics in the population. Although cancer incidence and mortality in Brunei Darussalam have been increasing for the past 10 years, there are still no data available on the proportion of Brunei cancer patients carrying germline or somatic mutations in their cancer predisposing gene. *BRCA1* and *BRCA2* gene frequencies in breast and ovarian cancer patients in other East-Asian populations have been continuously researched on which had led to the discovery of potential founder mutations [29,39,55,65]. Notably, identifying who should be offered cancer genetic test in the Asian community remains challenging as the currently available guidelines for testing have been shown to omit at least 20% of patients carrying *BRCA* mutations from being tested [21], suggesting the testing criteria on *BRCA1* and *BRCA2* germline mutations which have been well established in the Caucasian population were not readily applicable to the Asian population.
Our study, which is the first genetic study of its kind in Brunei, showed that the overall combined frequency of germline pathogenic *BRCA1* and *BRCA2* mutation carriers among 120 recruited Brunei’s breast cancer patients was 5% (*n* = 6), which is lower than those reported at 12.3% in women of European descendent [66]. Our data are relatively similar to previously reported prevalence from other Asian countries in particular from the South-East Asian region which is 4.7% in Malaysia [21] and 5.1% in the Philippines [39] except for Singapore [19] and Vietnam [40] which were reported at 17.4% and 0.8%, respectively. Interestingly, other Asian countries outside of the South-East Asian region had reported a relatively higher prevalence of *BRCA1* and *BRCA2* mutations which was almost similar (or higher for some) to the findings reported in European women with14.0% in Korea [67] and 24.7% in Pakistan [68]. Japan [69], Hong Kong [54,55] and China [20] however, reported a prevalence of 4.2%, 7.9% to 8.8%, and 8.3%, respectively. Comparatively, all these countries had reported prevalence of germline mutations in both *BRCA1* and *BRCA2* genes while all germline *BRCA* mutations identified in our study were attributed to *BRCA2* gene only.Our findings were consistent with those from all the aforementioned Asian countries where most of the germline pathogenic *BRCA* mutations in the Brunei breast cancer patients were identified in the *BRCA2* gene compared to *BRCA1* which was reported to be more affected in the European women [66].
Our study showed that one recurrent deleterious frameshift mutation, *BRCA2*c.5164_5165delAG (S1722Yfs*1725), was identified in 3 (2.5%) patients of Chinese ethnicity. In particular two of the affected patients, 4G-004 and 4G-003, were related to each other (mother and daughter, respectively). This mutation was suggested to have a founder effect in the Southern China province population. While it was unknown whether our Chinese index cases ancestry were originally from the Southern China, there was still a probability that the occurrence of this mutation might be linked to a common ancestral origin. Moreover, this mutation has also been reported in the Chinese ethnicity in Malaysia [34] and Singapore [18] which further support the probability of the founder mutation theory. However, it is acknowledged that the probability could be slightly lowered due to the fact that two out of three of the carriers of this mutation were relatives where the variant could have been inherited from their maternal side. Although the other two deleterious frameshift*BRCA2* mutations identified in this study only occur in one (0.8%) of the study population, the mutations c.3170_3174delAGAAA (K1057Tfs*1064) and c.1763_1766delATAAA (N588Sfs*612) had each been reported as a founder mutation in the French-Canadian [52]and Colombian[51] populations respectively. The probability of these two mutations being linked to the two populations was highly unlikely as the carriers were both of Malay ethnicity, and the family history from both carriers did not support a common ancestral origin with the aforementioned populations. Interestingly, in the South-East Asia (SEA) population, the *BRCA2* mutation c.1763_1766delATAA (N588Sfs*612) was only ever reported in a breast cancer patient in Sarawak, Malaysia who was diagnosed <40 years old with triple negative breast cancer and family history of breast cancer [33].This observation suggests that all populations have different population genetic predisposition towards breast cancer. Pathogenic mutations determined as a founder effect in one population may only be detected in a small frequency in other populations of different ancestral origin. Moreover, for the two patients identified with these mutations, there is a 50% chance that their family members carried the same *BRCA2* mutation that could result in the development of breast cancer in these family members.
The three aforementioned frameshift mutations introduced premature stop codon which was known to be associated with an increased risk of breast cancer. The effect of frameshift mutations resulting in the stop codon has been shown to destabilise BRCA mRNA leading to a haplo-insufficiency resulting in allelic imbalance [70]. This in turn caused a significant reduction in the expression ratio between the mutant and the wild-type alleles [70]. The allelic imbalance resulted in a decreased level of both BRCA transcripts and proteins contributing to the increased risk of breast cancer [70].The resulting BRCA2 truncated protein from the three identified pathogenic variants in our study showed a loss of important domains, including: (1) the BRC repeats domain (all for c.1763_1766delATAAA, BRC-2 to BRC-8 for c.3170_3174delAGAAA, BRC-6 to BRC-8 for c.5164_5165delAG); (2) the DNA binding domain (DBD); and (3) the two nuclear localisation signals (NLS) in the C-terminus region (S2 Fig).The highly conserved eight BRC repeat domains and the DNA binding domains in the BRCA2 protein mediate the interaction of ssDNA and/or dsDNA with RAD51 molecules in the homologous recombination (HR) regulated DNA repair pathway. In HR regulated pathway, BRCA2 is localised onto sites of dsDNA break by forming complex with other proteins including BRCA1 and PALB2, before it mediates the loading of RAD51 onto the ssDNA and initiate the repair. Loss of these RAD51-interacting domains in the BRCA2 protein prevent DNA repair in error-free HR regulated pathway, allowing the error-prone non-homologous end joining (NHEJ) pathway to take over. Moreover, it has been demonstrated that the deletions of all RAD51-interacting domains cause embryonic lethality in mice, but deletion of several BRC repeats motif showed a less severe phenotype although it was observed that the mice died very young from cancer development [71]. The DBD in BRCA2 was also involved in transcriptional activity where it bound ssDNA before drawing histone modifiers which led to the initiation of the transcriptional process [10]. The loss of the two NLS in the C-terminus region due to the truncation was reported to result in the mutant BRCA2 being cytoplasmic since it could not be translocated into the nucleus, hence causing it to become non-functional [72].
One likely pathogenic missense mutation was identified in the only patient who have no family history of cancers at all (S5 Table). *BRCA2* mutation c.8524C>T (R2842C) was located in the BRCA2 DNA binding domain suggesting it can affect the protein function. An assessment made on the clinical relevance of VUS identified in the BRCA2 DBD by using a validated functional assay of BRCA2 homologous recombination (HR) DNA-repair activity had showed the mutation R2842C had intermediate or partial effects on BRCA2 function [57]. Another functional assessment of human *BRCA2* variants using a mouse embryonic stem cell (mESC)-based assay supported that although the mutation R2842C is able to complement the loss of cell viability, its capacity to perform BRCA2 function i.e., homology directed repair (HDR) showed more than 50% reduction in HDR capacity compared with wild-type BRCA2 expressing cells[58,59].These results suggested that the mutation R2842C is characterized as a hypomorphic variant in which the studies concluded that the mutation is intermediate between pathogenic and likely pathogenic variants [58,59]. In our study, the effect of thehypomorphic*BRCA2* germline mutation R2842C was observed in patient 2G-022, in which the patient had an increased susceptibility to familial breast and/or ovarian cancers even though she did not have any family history of cancers at all. Notably, none of the founder mutations found in the SEA population were identified in our study population.
Similar to other genetic variation analysis conducted in other populations, 41 (43.2%) of the identified variants in the study population were classified as VUS (S3 Table). The overall combined frequency of patients with *BRCA1* and *BRCA2* VUS in the study was 35 (29.2%), in which 6 patients have both *BRCA1* and *BRCA2* VUS. Our findings are higher than those reported in other populations, such as 5.7% in European [66], and 1.6% in Malaysian [21] women, respectively. It has been shown that the prevalence of VUS in a study population was inversely correlated with the total number of individuals tested [66]. Hence, if our total study cohort population was higher than 120, our prevalence could be relatively similar with other countries’ findings as demonstrated in three other Asian countries’ studies conducted comprising over 2500 breast cancer patients; namely China [20], Malaysia [21], and Japan [69].
Collectively, Brunei *BRCA2* carriers exhibited almost the same phenotypic association pattern as other *BRCA2* carriers in China [20] and Malaysia [21], where Brunei *BRCA2* carriers were found to be more likely to have family history of breast and/or ovarian cancers, and having more first-degree relatives affected with breast cancer. Consistent with other studies, our findings showed that TNBC is not significantly associated with *BRCA2* carriers[17,19,21].
It is acknowledged that this study is limited by the small size of the study population even though it was the first and largest cohort study for genetic testing in Brunei. Future study on a larger cohort of study population could confirm our findings on the prevalence of germline mutations in the Brunei breast cancer population. Moreover, it could also provide a more comprehensive data for phenotypic characteristics of predisposing carriers in our breast cancer population attributed to each gene. Our current study showed that none of our study population tested for *BRCA1* and *BRCA2* large rearrangements showed positive for the test. Therefore, there are no data on the contribution of large rearrangement of *BRCA1*and *BRCA2* in the Brunei breast cancer population presented in this thesis. Given the constraint in getting resources for performing large rearrangements analysis in some of the study population (Batch 2), there is an approximately 10% probability that some carriers may have been missed in this study [19].
## Conclusions
The findings from this study have highlighted the contribution of genetics, specifically *BRCA1* and *BRCA2* genes in 120 unselected series of Brunei breast cancer population. The prevalence of germline *BRCA1* and *BRCA2* mutation carriers among Brunei breast cancer patients (5%) is similar to that of other Asian populations confirming the difference in contribution of *BRCA1* and *BRCA2* in both the Caucasian and Asian populations. One *BRCA2* mutation observed only in Brunei breast cancer population of Chinese ethnicity contributes to the probability of the mutation being a founder effect in the Southern Chinese population. Future studies should investigate the contribution of germline mutations of *BRCA1* and *BRCA2* genes in a larger case-control cohort study of Brunei breast cancer population to confirm our findings.
## Data Availability
All relevant data are within the manuscript and its Supporting Information files.
## Supporting information
**S1 Fig. The study strategy to detect *BRCA1* and *BRCA2* mutations.**
**S2 Fig. Schematic presentation of truncated BRCA2 protein in the study population.** The three identified *BRCA2* pathogenic mutations, c.1763\_1766delATAAA, c.3170\_3174delAGAAA and c.5164_5165delAG led to BRCA2 protein truncation at amino acids positions 612, 1064, and 1725 respectively. The truncation caused the loss of important domains affecting the function of BRCA2 predominantly in the HR-regulated DNA repair pathway.
**S1 Table. Deleterious mutations identified in the Brunei breast cancer patients.***, Termination; AA, amino acid; AF, Allele Frequency; Freq, Frequency; FS, Frameshift; Nov, Novel; Ref, Reference; Rep, Reported.
**S2 Table. Damaging missense variants identified in the Brunei breast cancer patients.** AA, amino acid; AF, Allele Frequency; B, Benign; D, Damaging; Freq, Frequency; N, Neutral; NA, Not Available; Nov, Novel; PrD, Probably Damaging; Ref, Reference; Rep, Reported; T, Tolerated.
**S3 Table.Missense variants identified in the Brunei breast cancer patients.** AA, amino acid; AF, Allele Frequency; B, Benign; D, Damaging; Freq, Frequency; N, Neutral; NA, Not Available; Nov, Novel; PoD, Possibly Damaging; PrD, Probably Damaging; Ref, Reference; Rep, Reported; T, Tolerated; VUS, Variant of uncertain significance.
**S4 Table. Synonymous variants identified in the Brunei breast cancer patients.** AA, amino acid; AF, Allele Frequency; Freq, Frequency; NA, Not Available; Nov, Novel; Rep, Reported.
**S5 Table. Characteristics of the Brunei breast cancer patients with deleterious and damaging missense mutations.**+, Positive; -, Negative; ‘XX, year diagnosed or deceased; AA, Amino acid; Aff, Affected; Au, Aunt; Bil., Bilateral; Br, Breast; Bro, Brother; Ca, Cancer; Chi, Chinese; Cou, Cousin; Dau, Daughter; de., deceased; dx., diagnosed; DC, Ductal carcinoma; DCIS, Ductal carcinoma in situ; ER, Oestrogen receptor; Eth, Ethnicity; F, Female; Fa, Father; Gen, Gender; GrMo, Grandmother; Her2, Human Epidermal Growth Receptor-2; IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma; L, Left; Liv, Liver; Lu, Lung; M, Male; Mal, Malay; Mat, Maternal; Mo, Mother; O, Older; Ov, Ovarian; Pat, Paternal; PR, Progesterone receptor; R, Right; Rec, Rectal; Sis, Sister; Sync, Synchronous; Uni, Unilateral; Y, Younger; yr., years.
## Acknowledgements
We sincerely acknowledge all the doctors, nurses and staff from TBCC for their cooperation and also to CRM and First Base Laboratories Sdn Bhd for their contribution to the study. We would like to thank our undergraduate students; Jacinda Lim Xin Yan and Hon Kar Yee; who have taken a small project under this study. Finally, we would like to express our gratitude to all patients who have participated in our research study. MRWHAH received a grant from Universiti Brunei Darussalam to fund the initial part of this study [UBD/PNC2/2/RG/1(186))]
* Received October 12, 2024.
* Revision received October 12, 2024.
* Accepted October 13, 2024.
* © 2024, Posted by Cold Spring Harbor Laboratory
This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)
## References
1. 1.Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.Int J Cancer. 2019;144:1941–53. doi: 10.1002/ijc.31937
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/ijc.31937&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=30350310&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
2. 2.Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5:77–106. doi: 10.1016/j.gendis.2018.05.001
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.gendis.2018.05.001&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=30258937&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
3. 3.Miki Y, Swensen J, Shattuck-Eidens D, Futreal P, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene *BRCA1*. Science. 1994;266(5182):66–71.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Mzoic2NpIjtzOjU6InJlc2lkIjtzOjExOiIyNjYvNTE4Mi82NiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDI0LzEwLzEzLzIwMjQuMTAuMTIuMjQzMTUzNzUuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)
4. 4.Wooster R, Neuhausen S, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, *BRCA2*, to chromosome 13q12-13. Science. 1994;265:2088–90.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Mzoic2NpIjtzOjU6InJlc2lkIjtzOjEzOiIyNjUvNTE4MS8yMDg4IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjQvMTAvMTMvMjAyNC4xMC4xMi4yNDMxNTM3NS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=)
5. 5.Xu B, Kim S, Kastan M. Involvement of *Brca1* in S-Phase and G2-Phase checkpoints after ionizing irradiation. Mol Cell Biol. 2001;21(10):3445–50.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoibWNiIjtzOjU6InJlc2lkIjtzOjEwOiIyMS8xMC8zNDQ1IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjQvMTAvMTMvMjAyNC4xMC4xMi4yNDMxNTM3NS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=)
6. 6.Starita L, Parvin J. The multiple nuclear functions of *BRCA1*: transcription, ubiquitination and DNA repair. CurrOpin Cell Biol. 2003;15:345–50.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0955-0674(03)00042-5&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=12787778&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
[Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000183512800014&link_type=ISI)
7. 7.Davies O, Pellegrini L. Interaction with the *BRCA2* C-terminus protects RAD51-DNA filaments from disassembly by BRC repeats. Nat Struct Mol Biol. 2007;14:475–83. doi:10.1083/nsmb1251.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nsmb1251&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=17515903&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
[Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000247029900012&link_type=ISI)
8. 8.Tassone P, Di Martino M, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, et al. Loss of *BRCA1* function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther. 2009;8(7):648–53.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1158/1535-7163.MCT-08-0853&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=19333003&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
[Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000266248800020&link_type=ISI)
9. 9.Clark S, Rodriguez A, Snyder R, Hankins G, Boehning D. Structure-Function of the tumor suppressor BRCA1. Comput Struct Biotec. 2012;1(1):e201204005.
10. 10.1. Chen C
Orr KS, Savage KI. The *BRCA1* and *BRCA2* Breast and Ovarian Cancer Susceptibility Genes – Implications for DNA Damage Response, DNA Repair and Cancer Therapy. In: Chen C, editors. Advances in DNA Repair. London: IntechOpen; 2015. p. 217–53.
11. 11.Xu B, O’Donnell AH, Kim ST, Kastan MB. Phosphorylation of Serine 1387 in *Brca1* is specifically required for the Atm-mediated S-Phase checkpoint after ionizing irradiation. Cancer Res. 2002;62:4588–91.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoiY2FucmVzIjtzOjU6InJlc2lkIjtzOjEwOiI2Mi8xNi80NTg4IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjQvMTAvMTMvMjAyNC4xMC4xMi4yNDMxNTM3NS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=)
12. 12.Fabbro M, Savage K, Hobson K, Deans AJ, Powell SN, McArthur GA, et al. *BRCA1-BARD1* complexes are required for *p53*Ser-15 phosphorylation and a G1/S arrest following ionizing radiation-induced DNA damage. J Biol Chem. 2004;279(30):31251–8.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamJjIjtzOjU6InJlc2lkIjtzOjEyOiIyNzkvMzAvMzEyNTEiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyNC8xMC8xMy8yMDI0LjEwLjEyLjI0MzE1Mzc1LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==)
13. 13.Deng CX. *BRCA1*: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 2006;34(5):1416–26.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/nar/gkl010&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=16522651&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
[Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000236432900021&link_type=ISI)
14. 14.Park MA, Seok YJ, Jeong G, Lee JS. SUMO1 negatively regulates BRCA1-mediated transcription, via modulation of promoter occupancy. Nucleic Acids Res. 2008;36(1):263–83. doi:10.1093/nar/gkm969.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/nar/gkm969&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=18025037&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
[Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000252545100033&link_type=ISI)
15. 15.Roy R, Chun J, Powell SN. *BRCA1* and *BRCA2:* different roles in a common pathway of genome protection. Nat Rev Cancer. 2016;12(1):68–78.
16. 16.Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, the *BRCA1* and *BRCA2* Cohort Consortium. Risks of breast, ovarian and contralateral breast cancer for *BRCA1* and *BRCA2* mutation carriers. JAMA. 2017;317(23):2402–16. doi:10.1001/jama.2017.7112.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2017.7112&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=28632866&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
17. 17.Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among *BRCA1* and *BRCA2* mutation carriers: results from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA). Cancer EpidemBiomar. 2012;21(1):134–47. doi:10.1158/1055-9965.EPI-11-0775.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiY2VicCI7czo1OiJyZXNpZCI7czo4OiIyMS8xLzEzNCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDI0LzEwLzEzLzIwMjQuMTAuMTIuMjQzMTUzNzUuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)
18. 18.Wong ESY, Shekar S, Chan CHT, Hong LZ, Poon SY, Silla T, et al. Predictive Factors for *BRCA1* and *BRCA2* Genetic Testing in an Asian Clinic-Based Population. PLoS ONE. 2015;10(7):e0134408.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0134408&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=26221963&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
19. 19.Wong ESY, Shekar S, Met-Domestici M, Chan C, Sze M, Yap YS, et al. Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore. Genom Med. 2016;1:15003. doi:10.1038/npjgenmed.2015.3.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/npjgenmed.2015.3&link_type=DOI)
20. 20.Lang GT, Shi JX, Hu X, Zhang CH, Shan L, Song CG, et al. The spectrum of *BRCA*-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing. Int J Cancer. 2017;141:129–42.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/ijc.30692&link_type=DOI)
21. 21.Wen WX, Allen J, Lai KN, Mariapun S, Hasan SN, Ng PS, et al. Inherited mutations in *BRCA1* and *BRCA2* in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. J Med Genet. 2018;55:97–103. doi:10.1136/jmedgenet-2017-104947.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToiam1lZGdlbmV0IjtzOjU6InJlc2lkIjtzOjc6IjU1LzIvOTciO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyNC8xMC8xMy8yMDI0LjEwLjEyLjI0MzE1Mzc1LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==)
22. 22.Wallace AJ. New challenges for BRCA testing: a view from the diagnostic laboratory. Eur J Hum Genet. 2016;24:S10–8. doi:10.1038/ejhg.2016.94.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/ejhg.2016.94&link_type=DOI)
23. 23.Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline *BRCA* mutation. New Engl J Med. 2017;377:523–33. doi:10.1056/NEJMoa1706450.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa1706450&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=28578601&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
24. 24.Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, et al. Biological and clinical evidence for somatic mutations in *BRCA1* and *BRCA2* as predictive markers for Olaparib response in high-grade serous ovarian cancers in the maintenance setting. Oncotarget. 2017;8(27):43653–61.
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
25. 25.Department of Economic Planning and Development (DEPD). Brunei Darussalam key indicators (BDKI) [Internet]. Brunei Darussalam: DEPD; 2018 [accessed 2019 Mar 21]. Available from: [http://www.depd.gov.bn/DEPD%20Documents%20Library/DOS/BDKI/BDKI_2018.pdf](http://www.depd.gov.bn/DEPD%20Documents%20Library/DOS/BDKI/BDKI_2018.pdf)
26. 26.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca-Cancer J Clin. 2018;68:394–424.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3322/caac.21492&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=30207593&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
27. 27.Chong VH, Telisinghe PU. Rising incidence of breast cancer in Brunei Darussalam. Brunei Int Med J. 2011;7(5):260–8.
28. 28.Tan S, Abdullah MS, Telisinghe PU, Ramasamy R. Breast cancer in Brunei Darussalam – Incidence and the role of evaluation of molecular markers. Brunei Int Med J. 2011;7(5):250–9.
29. 29.SngJH, Ali AB, Lee SC, Zahar D, Wong JEL, Blake V, et al. *BRCA1* c.2845insA is a recurring mutation with a founder effect in Singapore Malay women with early onset breast/ovarian cancer. J Med Genet. 2003;40:e117.
[FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6OToiam1lZGdlbmV0IjtzOjU6InJlc2lkIjtzOjEwOiI0MC8xMC9lMTE3IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjQvMTAvMTMvMjAyNC4xMC4xMi4yNDMxNTM3NS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=)
30. 30.Ho GH, Phang BH, Ng ISL, Law HY, Soo KC, Ng EH. Novel Germline *BRCA1* Mutations Detected in Women in Singapore who Developed Breast Carcinoma before the Age of 36 Years. Cancer. 2000;89:811–6.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/1097-0142(20000815)89:4<811::AID-CNCR13>3.0.CO;2-R&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=10951344&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
[Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000088753500013&link_type=ISI)
31. 31.Lim YL, Iau PTC, Ali AB, Lee SC, Wong JEL, Putti TC, et al. Identification of novel *BRCA* large genomic rearrangements in Singapore Asian breast and ovarian patients with cancer. Clin Genet. 2007;71:331–342.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/j.1399-0004.2007.00773.x&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=17470134&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
32. 32.Thirthagiri E, Lee SY, Kang P, Lee DS, Toh GT, Selamat S, et al. Evaluation of *BRCA1* and *BRCA2* mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res.2008;10:R59. doi:10.1186/bcr2118.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/bcr2118&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=18627636&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
33. 33.Yang XR, Devi BCR, Sung H, Guida J, Mucaki EJ, Xiao Y, et al. Prevalence and spectrum of germline rare variants in *BRCA1/2* and *PALB2* among breast cancer cases in Sarawak, Malaysia. Breast Cancer Res Treat. 2017;165(3):687–97. doi:10.1007/s10549-017-4356-8.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10549-017-4356-8&link_type=DOI)
34. 34.Ng PS, Wen WX, Fadlullah MZH, Yoon SY, Lee SY, Thong MK, et al. Identification of germline alterations in breast cancer predisposition genes among Malaysian breast cancer patients using panel testing. Clin Genet. 2016. doi: 10.1111/cge.12735.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/cge.12735&link_type=DOI)
35. 35.Balraj P, Khoo ASB, Volpi L, Tan JAMA, Nair S, Abdullah H. Mutation Analysis of the *BRCA1* Gene in Malaysian Breast Cancer Patients. Singapore Med J. 2002;43(4):194–7.
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=12188064&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
36. 36.Toh GT, Kang P, Lee SSW, Lee DSC, Lee SY.*BRCA1* and *BRCA2* Germline Mutations in Malaysian Women with Early-Onset Breast Cancer without a Family History. PLoS ONE. 2008;3(4):e2024. doi:10.1371/journal.pone.0002024.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0002024&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=18431501&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
37. 37.Kang P, Mariapun S, Phuah SY, Lim LS, Liu J, Yoon SY, et al. Large *BRCA1* and *BRCA2* genomic rearrangements in Malaysian high-risk breast-ovarian cancer families. Breast Cancer Res Treat.2010;124:579–84.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10549-010-1018-5&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=20617377&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
38. 38.Tria IV F, Ang D, Andal JJ, Que FV, Cabral LK, Dimalibot R, et al. Prevalence of Germline *Brca1* and *Brca2* Mutation Among Filipinos. Cancer Res J. 2019;7(3):79–86. doi: 10.11648/j.crj.20190703.12
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.11648/j.crj.20190703.12&link_type=DOI)
39. 39.Matsuda MLDL, Liede A, Kwan E, Mapua CA, Cutiongco EMC, Tan A, et al.*BRCA1* and *BRCA2* mutations among breast cancer patients from the Philippines. Int. J. Cancer. 2002;98:596–603.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/ijc.10194&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=11920621&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
[Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000174171800016&link_type=ISI)
40. 40.Ginsburg OM, Dinh NV, To TV, Quang LH, Linh ND, Duong BTH, et al. Family history, *BRCA* mutations and breast cancer in Vietnamese women. Clin Genet. 2010.doi: 10.1111/j.1399-0004.2010.01545.x.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/j.1399-0004.2010.01545.x&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=20950396&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
41. 41.Thuan TV, Chu NV, Khoa PH, Quang NT, Tu DV, Tho NTQ, et al. A Novel *BRCA1* Gene Mutation Detected with Breast Cancer in a Vietnamese Family by Targeted Next-Generation Sequencing: A Case Report. Breast Cancer Basic Clin Res.2020;14:1–4. doi: 10.1177/1178223420901555
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1177/1178223420901555&link_type=DOI)
42. 42.Patmasiriwat P, Bhothisuwan K, Sinilnikova OM, Chopin S, Methakijvaroon S, Badzioch M, et al. Analysis of Breast Cancer Susceptibility Genes *BRCA1* and *BRCA2* in Thai Familial and Isolated Early-Onset Breast and Ovarian Cancer. Hum Mutat. 2002;520. doi: 10.1002/humu.9049
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/humu.9049&link_type=DOI)
43. 43.Jadsri S, Chareonsirisuthigul T, Rerkamnuaychoke B, Dejsuphong D, Tunteeratum A, Mahasirimongkol S. *BRCA1* and *BRCA2* Large Genomic Rearrangements Screening in Thai Familial Breast Cancer Patients by Multiplex Ligation-dependent Probe Amplification (MLPA). Naresuan University Journal: Science and Technology. 2016;24(2).
44. 44.Purnomosari D, Paramita DK, Aryandono T, Pals G, van Diest PJ. A novel *BRCA2* mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing. J Clin Path. 2005;58:493–9. doi:10.1136/jcp.2004.020388
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToiamNsaW5wYXRoIjtzOjU6InJlc2lkIjtzOjg6IjU4LzUvNDkzIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjQvMTAvMTMvMjAyNC4xMC4xMi4yNDMxNTM3NS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=)
45. 45.Purnomosari D, Pals G, Wahyono A, Aryandono T, Manuaba TW, Haryono SJ, et al. *BRCA1* and *BRCA2* germline mutation analysis in the Indonesian population. Breast Cancer Res Treat. 2007;106:297–304.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10549-006-9493-4&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=17972177&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
46. 46.Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, et al. Confirmation of *BRCA1* by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet.1994;8:399–404.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/ng1294-399&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=7894493&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
[Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1994PV68200023&link_type=ISI)
47. 47.Wagner T, Stoppa-Lyonnet D, FleischmannE, Muhr D, Pages S, Sandberg T, et al. Denaturing high-performance liquid chromatography detects reliably *BRCA1* and *BRCA2* mutations. Genomics.1999;62(3):369–76.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1006/geno.1999.6026&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=10644434&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
[Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000085089400006&link_type=ISI)
48. 48.Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, et al. Prevalence and predictors of *BRCA1* and *BRCA2* mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res.2006;66(16):8297–308.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoiY2FucmVzIjtzOjU6InJlc2lkIjtzOjEwOiI2Ni8xNi84Mjk3IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjQvMTAvMTMvMjAyNC4xMC4xMi4yNDMxNTM3NS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=)
49. 49.Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, Čech M, et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res.2018;46(W1):W537–44. doi:10.1093/nar/gky379.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/nar/gky379&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=29790989&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
50. 50.RichardsS, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–23. doi:10.1038/gim.2015.30
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/gim.2015.30&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=25741868&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
51. 51.Torres D, Bermejo JL, Rashid MU, Briceño I, Gil F, Beltran A, et al. Prevalence and Penetrance of *BRCA1* and *BRCA2* Germline Mutations in Colombian Breast Cancer Patients. Nat Sci Rep.2017;7:4713. doi:10.1038/s41598-017-05056-y.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41598-017-05056-y&link_type=DOI)
52. 52.Janavičius R. Founder *BRCA1/2* mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA Journal, 2010;1:397–412.
53. 53.Sun J, Meng H, Yao L, Meng L, Bai J, Zhang J, et al. Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients. Clin Cancer Res. 2017;23(20):6113–9. doi: 10.1158/1078-0432.CCR-16-3227.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6ImNsaW5jYW5yZXMiO3M6NToicmVzaWQiO3M6MTA6IjIzLzIwLzYxMTMiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyNC8xMC8xMy8yMDI0LjEwLjEyLjI0MzE1Mzc1LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==)
54. 54.Kwong A, Shin VY, Au CH, Law FBF, Ho DN, Ip BK, et al. Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel. J Mol Diagn. 2016;18:580–94. doi: 10.106/j.jmoldx.2016.03.005.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.106/j.jmoldx.2016.03.005&link_type=DOI)
55. 55.Kwong A, Ho JCW, Shin VY, Kurian AW, Tai E, Esserman LJ, et al. Rapid detection of *BRCA1/2* recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panel. Oncotarget. 2018;9(8):7832–43.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.18632/oncotarget.23471&link_type=DOI)
56. 56.Guidugli L, Pankratz VS, Singh N, Thompson J, Erding CA, Engel C, et al. A classification model for BRCA2 DNA binding domain missense variants based on homology directed repair activity. Cancer Res. 2013;73(1):265–75. doi:10.1158/0008-5472.CAN-12-2081.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoiY2FucmVzIjtzOjU6InJlc2lkIjtzOjg6IjczLzEvMjY1IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjQvMTAvMTMvMjAyNC4xMC4xMi4yNDMxNTM3NS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=)
57. 57.Guidugli L, Shimelis H, Masica DL, Pankratz VS, Lipton GB, Singh N, et al. Assessment of the clinical relevance of *BRCA2* missense variants by functional and computational approaches. Am J Hum Genet. 2018; 102: 233–48.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ajhg.2017.12.013 Helena&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
58. 58.Mesman RLS, Calléja FMGR, Hendriks G, Morolli B, Misovic B, Devilee P, et al. The functional impact of variants of uncertain significance in *BRCA2*. Genet Med. 2019; 21: 293–302. doi: 10.1038/s41436-018-0052-2
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41436-018-0052-2&link_type=DOI)
59. 59.Caburet S, Heddar A, Dardillac E, Creux H, Lambert M, Messiaen S, et al. Homozygous hypomorphic*BRCA2* variant in primary ovarian insufficiency without cancer or Fanconi anaemia trait. J Med Genet. 2020; : 1–10. doi:10.1136/jmedgenet-2019-106672.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToiam1lZGdlbmV0IjtzOjU6InJlc2lkIjtzOjg6IjU4LzIvMTI1IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjQvMTAvMTMvMjAyNC4xMC4xMi4yNDMxNTM3NS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=)
60. 60.Bouwman P, van der Gulden H, van der Heiden I, Drost R, Klijn CN, Prasetyanti P, et al. A high-throughput functional complementation assay for classification of *BRCA1* missense variants. Cancer Discov. 2013; 3(10): 1142–55. doi:10.1158/2159-8290.CD-13-0094.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiY2FuZGlzYyI7czo1OiJyZXNpZCI7czo5OiIzLzEwLzExNDIiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyNC8xMC8xMy8yMDI0LjEwLjEyLjI0MzE1Mzc1LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==)
61. 61.Xu GP, Zhao Q, Wang D, Xie WY, Zhang LJ, Zhou H, et al. The association between BRCA1 gene polymorphism and cancer risk: a meta-analysis. Oncotarget. 2018; 9(9): 8681–94.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.18632/oncotarget.24064&link_type=DOI)
62. 62.Park JS, Nam EJ, Park HS, Han JW, Lee JY, Kim J, et al. Identification of a novel *BRCA1* pathogenic mutation in Korean patients following reclassification of *BRCA1* and *BRCA2* variants according to the ACMG Standards and Guidelines using relevant ethnic controls. Cancer Res Treat. 2017; 49(4): 1012–21. doi: 10.4143/crt.2016.433
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.4143/crt.2016.433&link_type=DOI)
63. 63.Findlay GM, Daza RM, Martin B, Zhang MD, Leith AP, Gasperini M, et al. Accurate classification of *BRCA1* variants with saturation genome editing. Nature. 2018; 562(7726): 217–22. doi:10.1038/s41586-018-0461-z.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41586-018-0461-z&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=30209399&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
64. 64.Sigurdson AJ, Hauptmann M, Chatterjee N, Alexander BH, Doody MM, Rutter JL, et al. Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer. 2004; 4(9).
65. 65.Karami F, Mehdipour P. A comprehensive focus on global spectrum of *BRCA1* and *BRCA2* mutations in Breast Cancer. Biomed Res Int. 2013: 1–21.
66. 66.Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, et al. *BRCA1* and *BRCA2* mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer.2009; 115(10): 2222–33. doi: 10.1002/cncr.24200.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/cncr.24200&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=19241424&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
[Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000265617100025&link_type=ISI)
67. 67.Kim HN, Shin MH, Lee R, Park MH, Kweon SS. Novel Germline Mutations of *BRCA1* and *BRCA2* in Korean Familial Breast Cancer Patients. Chonnam Med J. 2019; 55: 99–103. doi:10.4068/cmj.2019.55.2.99.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.4068/cmj.2019.55.2.99&link_type=DOI)
68. 68.Rashid MU, Muhammad N, Naeemi H, Khan FA, Hassan M, Faisal S, et al. Spectrum and prevalence of *BRCA1/2* germline mutations in Pakistani breast cancer patients: results from a large comprehensive study. Hered Cancer in Clin Pr. 2019; 17(27). doi: 10.1186/s13053-019-0125-5.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s13053-019-0125-5&link_type=DOI)
69. 69.Momozawa Y, Iwasaki Y, Parsons MT, Kamatani Y, Takahashi A, Tamura C, et al. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nature Comm. 2018; 9: 4083. doi: 10.1038/s41467-018-06581-8.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41467-018-06581-8&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
70. 70.Chen X, Truong TT, Weaver J, Bove BA, Cattie K, Armstrong BA, et al. Intronic alterations in *BRCA1* and *BRCA2*: effect on mRNA splicing fidelity and expression. Hum Mutat. 2006; 27(5): 427–435.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/humu.20319&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=16619214&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
[Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000237275900006&link_type=ISI)
71. 71.Donoho G, Brenneman MA, Cui TX, Donoviel D, Vogel H, Goodwin EH, et al. Deletion of *Brca2* exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice. Gene ChromosomeCanc.2003; 36: 317–31. doi: 10.1002/gcc.10148.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/gcc.10148&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=12619154&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F13%2F2024.10.12.24315375.atom)
[Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000181479000001&link_type=ISI)
72. 72.Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM. Truncated BRCA2 is cytoplasmic: Implications for cancer-linked mutations. PNAS. 1999; 96(24): 13920–5.
[Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMToiOTYvMjQvMTM5MjAiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyNC8xMC8xMy8yMDI0LjEwLjEyLjI0MzE1Mzc1LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==)